MarketWatch Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing.
Shares of Praxis Precision Medicines have hit their highest intraday level since March 2022.
Shares of Praxis Precision Medicines have hit their highest intraday level since March 2022.